Biocon Ltd said on Saturday (December 6) that it will fully integrate Biocon Biologics Ltd (BBL) as a wholly-owned subsidiary through a share-swap transaction, subject to regulatory and shareholder approvals.
The deal values Biocon Biologics at $5.5 billion.
The company will acquire the remaining stake held by Viatris (formerly Mylan) for $815 million, which includes a share-swap component priced at ₹405.78 per Biocon share. Biocon said it expects the integration to be completed by March 31, 2026.
The board has also approved the swap ratios for the transaction and cleared a proposal to raise up to ₹4,500 crore (about $500 million) through a qualified institutional placement, subject to shareholder approval.
Biocon said the move will simplify its corporate structure and strengthen Biocon Biologics’ strategic and financial flexibility as it expands its global biosimilars portfolio.
